Evaluation of diagnostic value of four tumor markers in bronchoalveolar lavage fluid of peripheral lung cancer

Li, Jian; Chen, Ping; Mao, Chaoming; Tang, Xinping; Zhu, Liangjun

doi:10.1111/ajco.12066

Cited by 14 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the clinical practical value of serum SCC-Ag is still controversial. The numerical changes of SCC-Ag do not specifically reflect cervical cancer; increased SCC-Ag levels have also been observed in patients with lung cancer, esophageal SCC and other benign diseases (36–38). More unfortunately, the autofit cut-off level of SCC-Ag is still a matter of debate partially due to the different disease stages of patient groups (39).…”

Section: Discussionmentioning

confidence: 97%

GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer

et al. 2017

View full text Add to dashboard Cite

GINS complex subunit 2 (GINS2), a member of the GINS complex, is involved in DNA replication. GINS2 is upregulated in a variety of aggressive tumors. However, its role in cervical cancer carcinogenesis remains to be elucidated. We investigated the clinical significance of GINS2 in patients with early-stage cervical cancer and its biological functions in cervical cancer progression. GINS2 expression was analyzed in cervical cancer cell lines and in 8 matched cervical cancer samples at the mRNA and protein levels using real-time PCR and western blotting, respectively. GINS2 protein expression in 155 paraffin-embedded cervical cancer specimens was validated using immunohistochemistry. Statistical analysis was used to evaluate its clinicopathological significance. Short hairpin RNA interference, anchorage-independent growth ability, colony formation assay, wound healing ability, Transwell assays and western blotting were used to determine the effects of GINS2 on the aggressive phenotype of cervical cancer cells. There was obvious upregulation of GINS2 in the cervical cancer cell lines and tumor specimens compared to that in the normal cervical tissues. Significant correlations were identified between GINS2 expression and squamous cell carcinoma antigen (SCC-Ag; P<0.001), deep stromal invasion (P=0.021), vital status (P<0.001), recurrence (P<0.001) and pelvic lymph node metastasis (PLNM; P<0.001). Moreover, patients with higher GINS2 expression had shorter overall survival (OS) compared to patients with low GINS2 expression. Multivariate analysis revealed that GINS2 may serve as an independent risk factor of poor prognosis in early-stage cervical cancer. In addition, GINS2 downregulation markedly suppressed cell proliferation and tumorigenic ability, as well as cell migration and invasion. Our findings suggest that GINS2 is a novel indicator of PLNM and a valuable prognostic biomarker in early-stage cervical cancer, and subsequently is a valuable molecular target for cervical cancer diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 97%

GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…However, single marker of lung cancer shows low diagnostic specificity and sensitivity, having poor value for the diagnosis of lung cancer (Leidinger et al, 2010). Therefore, there is a consensus that a combination of markers can increase the diagnostic specificity and sensitivity than single marker (Schneider et al, 2002;Farlow et al, 2010;Wang et al, 2013;Li et al, 2014). For example, in diagnosing some malignant tumors, such as prostate or ovarian cancer, by combining multiple biomarkers data, the diagnostic performance was improved rapidly than individual serum biomarker (Amsellem-Ouazana et al, 2005;Kim et al, 2012).…”

Section: Introductionmentioning

confidence: 99%

Prediction of Lung Cancer Based on Serum Biomarkers by Gene Expression Programming Methods

Chen²,

Cui³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

In diagnosis of lung cancer, rapid distinction between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) tumors is very important. Serum markers, including lactate dehydrogenase (LDH), C-reactive protein (CRP), carcino-embryonic antigen (CEA), neurone specific enolase (NSE) and Cyfra21-1, are reported to reflect lung cancer characteristics. In this study classification of lung tumors was made based on biomarkers (measured in 120 NSCLC and 60 SCLC patients) by setting up optimal biomarker joint models with a powerful computerized tool -gene expression programming (GEP). GEP is a learning algorithm that combines the advantages of genetic programming (GP) and genetic algorithms (GA). It specifically focuses on relationships between variables in sets of data and then builds models to explain these relationships, and has been successfully used in formula finding and function mining. As a basis for defining a GEP environment for SCLC and NSCLC prediction, three explicit predictive models were constructed. CEA and NSE are requentlyused lung cancer markers in clinical trials, CRP, LDH and Cyfra21-1 have significant meaning in lung cancer, basis on CEA and NSE we set up three GEP models-GEP 1(CEA, NSE, Cyfra21-1), GEP2 (CEA, NSE, LDH), GEP3 (CEA, NSE, CRP). The best classification result of GEP gained when CEA, NSE and Cyfra21-1 were combined: 128 of 135 subjects in the training set and 40 of 45 subjects in the test set were classified correctly, the accuracy rate is 94.8% in training set; on collection of samples for testing, the accuracy rate is 88.9%. With GEP2, the accuracy was significantly decreased by 1.5% and 6.6% in training set and test set, in GEP3 was 0.82% and 4.45% respectively. Serum Cyfra21-1 is a useful and sensitive serum biomarker in discriminating between NSCLC and SCLC. GEP modeling is a promising and excellent tool in diagnosis of lung cancer.

show abstract

“…A recent study by Li et al . identified that BALF was superior to serum specimens for detection of CEA, NSE, CYFRA21‐1 and SCC‐Ag. However, the value of some new markers such as USP8 for the diagnosis of peripheral pulmonary carcinoma in BALF was not clear.…”

Section: Resultsmentioning

confidence: 99%

The diagnostic value of tumor markers in bronchoalveolar lavage fluid for the peripheral pulmonary carcinoma

Shi

Zhao

Zhang

et al. 2015

Clinical Respiratory J

View full text Add to dashboard Cite

show abstract

Evaluation of diagnostic value of four tumor markers in bronchoalveolar lavage fluid of peripheral lung cancer

Abstract: The assay of these tumor markers in BALF may be used as a diagnostic tool to complement a cytological examination in the diagnosis of peripheral lung cancer.

Cited by 14 publications

References 28 publications

GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer

GINS2 is a novel prognostic biomarker and promotes tumor progression in early-stage cervical cancer

Prediction of Lung Cancer Based on Serum Biomarkers by Gene Expression Programming Methods

The diagnostic value of tumor markers in bronchoalveolar lavage fluid for the peripheral pulmonary carcinoma

Contact Info

Product

Resources

About